Rigel Pharmaceuticals (RIGL) Revenue (2010 - 2026)

Rigel Pharmaceuticals' Revenue history runs 16 years deep, the most recent figure standing at $58.8 million for Q1 2026.

• In Q1 2026, Revenue rose 10.28% year-over-year to $58.8 million; the TTM figure through Mar 2026 stood at $299.8 million (up 47.61% YoY), while the FY2025 annual figure was $294.3 million, up 64.15% from the prior year.
• Revenue was $58.8 million for Q1 2026 at Rigel Pharmaceuticals, down from $69.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $101.7 million in Q2 2025 to a low of $16.7 million in Q1 2022.
• Historically, Revenue has averaged $45.3 million across 5 years, with a median of $36.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Revenue tumbled 79.34% in 2022, then surged 176.01% in 2025.
• A 5-year view of Revenue shows it stood at $51.3 million in 2022, then tumbled by 30.2% to $35.8 million in 2023, then jumped by 60.92% to $57.6 million in 2024, then advanced by 21.19% to $69.8 million in 2025, then dropped by 15.74% to $58.8 million in 2026.
• The last three Revenue figures came in at $58.8 million (Q1 2026), $69.8 million (Q4 2025), and $69.5 million (Q3 2025), per Business Quant data.